6 Amendments of Laura AGEA related to 2016/2206(DEC)
Amendment 4 #
Motion for a resolution
Paragraph 5
Paragraph 5
5. Acknowledges that in 2015 the agencies proceeded with executing their work programmes as envisaged; notes however that the ongoing discussions regarding the revision of the Financial Regulation and the future multi-annual financial framework post-2020 present a valuable opportunity to take a forward look and to exploit these opportunities to implement positive change regarding the management of the agencies’ budgets, deliverables, possible and advisable agency mergers and their multiannual work programmes;
Amendment 15 #
Motion for a resolution
Paragraph 21
Paragraph 21
21. Highlights the benefits of sharing services, which enable consistent application of administrative implementing rules and procedures that concern human resources and finance issues, as well as the potential efficiency gains of sharing services between the agencies, in particular when considering the budget and staff reductions that the agencies are facing; calls on the Commission to submit, by the end of 2018, a plan to merge the common administrative functions of the agencies, in order to reduce expenditure and ensure that administrative tasks that do not give added value to the agencies' duties are reduced;
Amendment 16 #
Motion for a resolution
Paragraph 21 a (new)
Paragraph 21 a (new)
21a. Notes with concern that some agencies continue to have dual operational and administrative headquarters; regards it as essential that all dual headquarters which do not offer any operational added value should be done away with at the earliest opportunity;
Amendment 24 #
Motion for a resolution
Paragraph 29
Paragraph 29
29. Notes from the Network that all agencies already adopted generic rules on whistleblowing as part of the ethics guidelines on whistleblowing and in accordance with the provisions of the staff regulations; notes with concern however, that only 65 % of the agencies adopted additional internal rules on whistleblowing; acknowledges from the Network that, in the cases where the relevant rules are not yet in place, the process is ongoing with pending adoption; notes that in several cases, the agencies are waiting for guidance or input from the Commission before they can finalise their rules; acknowledges moreover that the rules should be finalised and implemented in the first half of 2017; calls on the agencies to ensure that they not only formally oblige officials to report irregularities of all kinds but also to lay down adequate protection for whistle-blowers, in accordance with the procedures applied within the European institutions; calls on the agencies which have not still adopted the internal whistleblowing rules to do so without delay, and equally calls on the Commission to provide the necessary guidance and approval where required;
Amendment 26 #
Motion for a resolution
Paragraph 30
Paragraph 30
30. Notes that out of the 16 agencies which use expert groups, scientific panels and committees, 13 took into account into their staffing policies the concerns raised by the Ombudsman’s own-initiative inquiry OI/6/2014/NF concerning the composition of the Commission expert groups; calls on the agencies to adhere to the highest standards in order to avoid conflicts of interest and to ensure that the work of the expert groups is totally transparent; encourages the remaining agencies to take the Ombudsman’s concerns into account as soon as possible;
Amendment 32 #
Motion for a resolution
Paragraph 32 a (new)
Paragraph 32 a (new)
32a. Points out that the role of many agencies is to provide assessments and opinions on products and services for EU citizens; stresses that every expert's report provided by the agencies must be based on the use of public data, as only then will the international scientific community be able to check and confirm it; notes that several agencies also use information that is protected as a trade secret; believes that agencies should publish all the sources they use for their assessments, even those covered by trade secrecy, when giving opinions on products which may adversely affect the health of EU citizens;